Merck KGaA Add to portfolio

DAXX:MRK, Jul 17, 07:22 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Today


News

Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod

MRK

Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod. Merck & Co., Inc. (NYSE: MRK) continues to find success with its product pipeline, with another of its treatment options receiving FDA approval. The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options. "RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options," Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Monday, July 15


News

A Pairs Prescription for CVS Stock and Merck

MRK

InvestorPlaceJuly 15, 2019, 2:55 PM UTC. When it comes to investing, a new price trend is something we all can enjoy. But when you can effectively hedge that bet with a pairs trade in CVS (NYSE:CVS) and Merck (NYSE:MRK), that’s a prescription for profits. It nearly goes without saying interest rate policy and the U.S. China trade war have been on most investors’ minds of late. Some days Wall Street is bullish, while on others, it’s seemingly the end of the world as we know it. But for MRK stock and CVS shareholders, real catalysts off and on the price charts are happening right now. On Thursday, the Donald Trump administration announced it is walking away from a plan to eliminate rebates large pharmaceutical companies pay to pharmacy benefits managers, which negotiate drug prices on behalf of buyers such as insurance companies. Shares of MRK stock look prone to a larger cycle of profit-taking following what I’ll call a period of bullish influenza after breaking out last July from a corrective base-on-base pattern.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, July 13


News

Bulls & Bears Of The Week: Costco, DuPont, IBM, Merck And More

MRK IBM

Bulls & Bears Of The Week: Costco, DuPont, IBM, Merck And More. Bearish calls included pharma and video game leaders and a retailer struggling to survive. While investors and analysts mulled over the latest stance by the Federal Reserve and looked forward to a new earnings reporting season, the big U.S. indexes ended last week around 2% higher — at or near all-time highs. DowDuPont spin-off DuPont de Nemours Inc (NYSE: DD) is well-positioned to generate value, according to Jayson Derrick's "New DuPont 'Built For Success,' BofA Says In Bullish Initiation." "6 Reasons Why Costco Is Dominating A Difficult Retail Market" by Wayne Duggan shows why Costco Wholesale Corporation (NASDAQ: COST) is defying the odds and thriving in the retail market and is a rare growth story among large-cap staple stocks.

Read Full Details

Topics:
  • Business
  • Financial
News

Better Buy: AbbVie vs. Merck

MRK ABBV

With its top-selling drug Humira under pressure from biosimilars, AbbVie has struggled mightily. Merck's upward momentum and AbbVie's malaise might make you think that the decision between these two stocks is an easy one to make. But there's a lot to consider as you choose between AbbVie and Merck. AbbVie's shares trade at just over 7.5 times expected earnings, making AbbVie one of the cheapest big pharma stocks on the market. The company has three products already on the market that should enjoy strong sales growth: cancer drugs Imbruvica and Venclexta, endometriosis pain drug Orilissa, and new immunology drug Skyrizi. Even better, though, AbbVie awaits regulatory approval of upadacitinib in treating rheumatoid arthritis.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Friday, July 12


News

Washington Worries Trigger Bearish Merck Options Trades

MRK

Merck shares are now down 8% in the past week, but at least one large option trader is betting there won’t be a Merck rebound anytime soon. Within a minutes time, likely the same trader sold an additional 1,250 of the same June 2020 Merck call options at the same $1.50 bid price via two additional trades. After all was said and done, the trading action represented a total bearish bet of $225,000 on Merck. Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades. Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there’s no surefire way to determine if an options trade is a standalone position or a hedge. In this case, given the trades were split up into three blocks, they could represent an institutional trader.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Friday’s Vital Data: Bed Bath & Beyond, CVS and Merck

MRK CVS

In early morning trading, futures on the Dow Jones Industrial Average are up 0.29%, and S&P 500 futures are higher by 0.22%. In the options pits, calls continued their usual leadership role on Thursday, while overall volume settled to average levels. A quick Google search following this week’s earnings release for ailing retailer, Bed Bath & Beyond, reveals a litany of ominous-sounding headlines. And, well, they’re all probably justified. For the fiscal first-quarter, the company posted a loss of $2.91 per share. CVS Health has been in decline for years, but scored a rare win yesterday after the White House halted plans that “would have curtailed rebates that drug manufacturers pay pharmacy benefit managers (PBMs) in return for winning placement of high-priced products on lists of drugs that insurers cover with affordable co-pays.”. Although CVS stock closed up 4.68% on the session, it was mostly a sell-the-news reaction.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, July 10


News

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019

MRK

Merck Highlights Commitment to HIV Research with Presentations for Investigational Anti-HIV Agent MK-8591 at IAS 2019. Business WireJuly 10, 2019, 10:45 AM UTC. Merck (MRK), known as MSD outside the United States and Canada, announced today that the results from studies evaluating MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), are scheduled to be presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) taking place July 21 – 24, 2019 in Mexico City. “Building upon our proud heritage in HIV, we are excited to share these latest findings for MK-8591,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Tolerability, safety and efficacy of MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine and lamivudine through 24 weeks in treatment-naïve adults with HIV-1 infection.

Read Full Details

Topics:
  • Business
  • Health
  • Technology

Monday, July 08


News

Merck Manuals Offers Guidance on Eliminating Asthma Triggers

MRK

KENILWORTH, N.J., July 8, 2019 /PRNewswire/ -- Asthma is one of the most prevalent chronic conditions afflicting children in the United States, and it's becoming more common. These triggers can cause asthma attacks and play a role in patients developing asthma in the first place. Patients and parents are rightfully focused on identifying specific asthma triggers for themselves or their children and eliminating those triggers from the home. But more and more research suggests environments that are too clean can actually limit children's tolerance of certain allergens. Emily J. Pennington, MD, Cleveland Clinic and author of the Merck Manuals chapter on asthma, offered some insight for parents and patients wondering how far is too far when it comes to eliminating asthma triggers at home.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Wednesday, July 03


News

Stocks making the biggest moves premarket: Tesla, Merck, Symantec, Canopy Growth & more

MRK TSLA

Merck — An analyst at Mizuho Securities initiated Merck with a "buy" rating and a price target of $97 per share, implying an upside of 13.4%. Symantec, Broadcom — Symantec shares soared more than 17% after Bloomberg News reported the company is in talks to be acquired by Broadcom. USANA Health Sciences — The company lowered its full-year earnings outlook and now sees its annual profit ranging between $3.70 per share and $4.10 a share. Dell, Microsoft, HP Inc — Nikkei reported that Dell, Microsoft, and HP were among a number of U.S. tech companies looking to shift "substantial" production operations out of China.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck Gets Boost From Analyst Buy Rating

MRK

Shares of pharmaceutical giant Merck gain after Mizuho Securities initiates coverage with a buy rating and a 12-month price target of $97 a share.

Read Full Details

Topics:
  • Business
  • Health
  • Financial